Viralkumar Bhanderi, MD
Medical Oncology · Tallahassee, FLNPI 1265518377
Payments from drug & device makers
Across 1,606 payments — averaging $4706.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3.1M
- Array Biopharma Inc$1.5M
- Pfizer$831K
- Takeda Pharmaceuticals U.S.A., Inc.$487K
- Eli Lilly$373K
- Boehringer Ingelheim International GmbH$181K
- plus $1.1M from 54 others
Across 10 payments — averaging $848.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$5K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
What the payments were for
- Speaking & faculty fees$4855%
- Food & beverage$7,57980%
- Education$1,37015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NINLARO$124
- FOUNDATIONONE$105
- FOUNDATIONONE HEME$105
- FOUNDATIONONE CDX$105
- FOUNDATIONFOCUS$105
- FOUNDATIONONE LIQUID$105
- THERASPHERE$103
How this compares
$7,559,143 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 84 | $1,182,277 |
| RevlimidLenalidomide | 49 | $775,686 |
| CabometyxCabozantinib S-Malate | 18 | $390,422 |
| CalquenceAcalabrutinib Maleate | 20 | $300,974 |
| VenclextaVenetoclax | 32 | $269,536 |
| JakafiRuxolitinib Phosphate | 16 | $264,342 |
| OrserduElacestrant Hcl | 11 | $240,545 |
| EliquisApixaban | 89 | $70,460 |
| ThalomidThalidomide | 13 | $60,964 |
| Everolimus | 24 | $38,262 |
| XareltoRivaroxaban | 30 | $22,178 |
| Abiraterone Acetate | 11 | $8,203 |
| Imatinib Mesylate | 38 | $4,646 |
| Exemestane | 23 | $3,087 |
| Hydroxyurea | 37 | $1,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Thalomid | $861 | $836,65062 claims |
| Exelixis Inc.Cabometyx | $139 | $390,42218 claims |
| AstraZenecaCalquence | $68,969 | $300,97420 claims |
| AbbVieVenclexta | $176,742 | $269,53632 claims |
| Incyte CorporationJakafi | $21,824 | $264,34216 claims |
| PfizerEliquis | $831,194 | $70,46089 claims |
| Johnson & JohnsonXarelto | $205 | $22,17830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Tallahassee
- Pareshkumar PatelTallahassee$2.4M
- Zeynep ErogluTampa$30.9M
- Manish PatelSarasota$29.7M
- Jad ChahoudTampa$21.8M
- Maen HusseinTavares$18.4M
- Patrick HwuTampa$18M
- Gail WrightHudson$13.8M
- Adil DaudTampa$13.3M
- Lowell HartFort Myers$10.1M
- Judy WangSarasota$9.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.